Cargando…

Factors associated with parathyroid hormone control in haemodialysis patients with secondary hyperparathyroidism treated with cinacalcet in real-world clinical practice: Mimosa study

BACKGROUND: Secondary hyperparathyroidism (SHPT) is frequent in haemodialysis (HD) patients. Oral cinacalcet-hydrochloride (HCl) decreases parathyroid hormone (PTH); however, real-life PTH data, according to Kidney Disease: Improving Global Outcomes (KDIGO) guidelines, are still lacking. Our goal is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rottembourg, Jacques, Ureña-Torres, Pablo, Toledano, Daniel, Gueutin, Victor, Hamani, Abdelaziz, Coldefy, Olivier, Hebibi, Hedia, Guincestre, Thomas, Emery, Corinne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	CKD-Mbd
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885690/ https://www.ncbi.nlm.nih.gov/pubmed/31807302 http://dx.doi.org/10.1093/ckj/sfz021

Ejemplares similares

Are oxyphil cells responsible for the ineffectiveness of cinacalcet hydrochloride in haemodialysis patients?
por: Rottembourg, Jacques, et al.
Publicado: (2018)

Disrupted tubular parathyroid hormone/parathyroid hormone receptor signaling and damaged tubular cell viability possibly trigger postsurgical kidney injury in patients with advanced hyperparathyroidism
por: Sato, Tetsuhiko, et al.
Publicado: (2019)

Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease
por: Ureña-Torres, Pablo A, et al.
Publicado: (2018)

Vitamin D, bone alkaline phosphatase and parathyroid hormone in healthy subjects and haemodialysed patients from West Africa: impact of reference ranges and parathyroid hormone generation assays on the KDIGO guidelines
por: Cavalier, Etienne, et al.
Publicado: (2018)

Multimodal treatment of calcific uraemic arteriolopathy (calciphylaxis): a case series
por: Russo, Domenico, et al.
Publicado: (2016)

Calcifying circulating cells: an uncharted area in the setting of vascular calcification in CKD patients
por: Cianciolo, Giuseppe, et al.
Publicado: (2016)

The effects of vitamin K supplementation and vitamin K antagonists on progression of vascular calcification: ongoing randomized controlled trials
por: Caluwé, Rogier, et al.
Publicado: (2016)

Is progression of coronary artery calcification influenced by modality of renal replacement therapy? A systematic review
por: Jansz, Thijs T, et al.
Publicado: (2018)

Calciphylaxis in a dialysis patient successfully treated with high-dose vitamin K supplementation
por: Christiadi, Daniel, et al.
Publicado: (2018)

Multi-intervention management of calcific uremic arteriolopathy in 24 patients
por: Harris, Claire, et al.
Publicado: (2018)

Achievement of 2009 and 2017 Kidney Disease: Improving Global Outcomes mineral and bone targets and survival in a French cohort of chronic kidney disease Stages 4 and 5 non-dialysis patients
por: Fouque, Denis, et al.
Publicado: (2018)

Is chronic kidney disease-mineral and bone disorder associated with the presence of endothelial progenitor cells with a calcifying phenotype?
por: Cianciolo, Giuseppe, et al.
Publicado: (2017)

Soluble klotho may be a marker of phosphate reabsorption
por: Tan, Sven-Jean, et al.
Publicado: (2017)

Gastrointestinal complications induced by sevelamer crystals
por: Yuste, Claudia, et al.
Publicado: (2017)

Placebo-controlled, randomized clinical trial of high-dose cholecalciferol in renal dialysis patients: effect on muscle strength and quality of life
por: Singer, Richard, et al.
Publicado: (2018)

Short-term effects of sevelamer-carbonate on fibroblast growth factor 23 and pulse wave velocity in patients with normophosphataemic chronic kidney disease Stage 3
por: Bouma-de Krijger, Annet, et al.
Publicado: (2019)

Small steps towards the potential of ‘preventive’ treatment of early phosphate loading in chronic kidney disease patients
por: Bover, Jordi, et al.
Publicado: (2019)

Quality of life with conservative care compared with assisted peritoneal dialysis and haemodialysis
por: Iyasere, Osasuyi, et al.
Publicado: (2018)

Association between long-term efficacy of cinacalcet and parathyroid gland volume in haemodialysis patients with secondary hyperparathyroidism
por: Tanaka, Motoko, et al.
Publicado: (2008)

Parathyroid Apoplexy Following Cinacalcet Treatment in Primary Hyperparathyroidism
por: Di Dalmazi, Giulia, et al.
Publicado: (2018)

Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes
por: Pereira, Luciano, et al.
Publicado: (2018)

Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis
por: Wolf, Myles, et al.
Publicado: (2019)

Clinical hemodialysis experience with percutaneous arteriovenous fistulas created using the Ellipsys® vascular access system
por: Hebibi, Hedia, et al.
Publicado: (2019)

SAT-349 Cinacalcet Resistant Tertiary Hyperparathyroidism with One Large Parathyroid Gland
por: Chaker, Bayan, et al.
Publicado: (2020)

Renal artery intervention utilizing carbon dioxide angiography
por: Sag, Alan A, et al.
Publicado: (2017)

Symptom burden in patients with chronic kidney disease not requiring renal replacement therapy
por: Brown, Stephanie A, et al.
Publicado: (2017)

Renal denervation using carbon dioxide renal angiography in patients with uncontrolled hypertension and moderate to severe chronic kidney disease
por: Hameed, Mohammed Awais, et al.
Publicado: (2017)

Patterns of progression of chronic kidney disease at later stages
por: Caravaca-Fontán, Fernando, et al.
Publicado: (2018)

The relationship between kidney function and quality of life among community-dwelling adults varies by age and filtration marker
por: Canney, Mark, et al.
Publicado: (2018)

Frailty and chronic kidney disease: current evidence and continuing uncertainties
por: Nixon, Andrew C, et al.
Publicado: (2018)

A scheme based on ICD-10 diagnoses and drug prescriptions to stage chronic kidney disease severity in healthcare administrative records
por: Friberg, Leif, et al.
Publicado: (2018)

Incorporating patient-reported symptom assessments into routine care for people with chronic kidney disease
por: van der Veer, Sabine N, et al.
Publicado: (2017)

The metabolomic quest for a biomarker in chronic kidney disease
por: Davies, Robert
Publicado: (2018)

The European Renal Association – European Dialysis and Transplant Association Registry Annual Report 2014: a summary
por: Pippias, Maria, et al.
Publicado: (2017)

Current trends in European renal epidemiology
por: Heaf, James
Publicado: (2017)

Low lean tissue mass is an independent risk factor for mortality in patients with stages 4 and 5 non-dialysis chronic kidney disease
por: Vega, Almudena, et al.
Publicado: (2017)

Clarifying the concept of chronic kidney disease for non-nephrologists
por: Perez-Gomez, Maria Vanessa, et al.
Publicado: (2019)

Impact of a phone app on nephrology referral
por: Oliva-Damaso, Nestor, et al.
Publicado: (2018)

Chronic kidney disease and urological disorders: systematic use of uroflowmetry in nephropathic patients
por: Lai, Silvia, et al.
Publicado: (2018)

Anticoagulant-related nephropathy: systematic review and meta-analysis
por: de Aquino Moura, Karolinny Borinelli, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_jcbk932300u5jj6fhf3siv9s8r